MagicRNA

    Focusing on Nucleic Acid Drug Delivery, Benefitting Patients with RNA Therapiesy

    MagicRNA

    Focusing on Nucleic Acid Drug Delivery, Benefitting Patients with RNA Therapies
  • About Us

    Focusing on Nucleic Acid Drug Delivery, Benefitting Patients with RNA Therapies.


    Shenzhen MagicRNA Biotech Co., Ltd., founded in 2021, focused on the nucleic acid delivery LNP, and we have successfully constructed the engineered cell-targeted lipid nanoparticle (EnC-LNP) platform. As ionizable amine lipid is the most important component of LNP, we have developed the proprietary lipid structure and hold the ionizable lipid library, with the core lipid (ILB-3132) now commercially available. We constructed specific EnC-LNP for cells from the immune system, central nervous system, and tumor cells. MagicRNA has deeply developed its pipelines based on the proprietary EnC-LNP.HN2301 (in vivo CAR-T producer), MagicRNA’ s leading pipeline, using T cell EnC-LNP encapsulated with CD19 CAR mRNA for the treatment of B cell-involved autoimmune diseases, has completed the Preclinical Candidate (PCC) stage and is under IND-Enabling now. HN2301 successfully reprogrammed the CD19 CAR T cells and induced the B cell depletion and reset in both blood and tissues in non-human primates (NHPs) and has verified the therapeutic effects on systemic lupus erythematosus (SLE) model mice. Other pipelines based on the EnC-LNP are under investigation now.